Dr. Umar

A combined microbiome–metabolome analysis demonstrated that Parkinson’s disease gut microbiota and metabolome show depletion of SCFA-producing taxa and major metabolic disturbances, revealing microbe–metabolite signatures relevant to neuroinflammation, nutrient deficits, and PD pathophysiology.

Metagenomic analysis of Chinese Parkinson’s disease patients identified a 25-gene gut microbial signature that robustly distinguishes Parkinson’s disease from controls, multiple system atrophy and Alzheimer’s disease, and can be implemented via real-time PCR as a clinically usable microbiome-based diagnostic index.

In an MPTP mouse model, acupuncture-gut-microbiota-parkinsons-disease interactions linked microbial normalization and pathway shifts to reduced neuroinflammation, preserved nigrostriatal dopamine neurons and improved motor and anxiety-like behaviors.

Large MWAS of PD identified three microbiome clusters: opportunistic pathogens enriched in PD, SCFA-producing commensals depleted, and probiotic genera expanded, partly in association with levodopa dose, providing concrete taxa for mechanistic and therapeutic exploration.

Integrative analysis of stool 16S data and metabolic modelling in Parkinson’s disease links specific taxa and sulfur- and GABA-related metabolic outputs to disease status, motor severity, non-motor symptoms, and constipation, defining candidate microbiome–metabolite signatures for future clinical and biomarker applications.

This study identifies distinct gut microbiota signatures in Parkinson’s disease patients with mild cognitive impairment, notably increased Porphyromonadaceae and decreased Blautia, which are linked to cognitive decline. These findings highlight potential microbiome markers and therapeutic targets for cognitive impairment in PD.

This pilot study identifies overlapping gut microbiome signatures in Parkinson’s disease patients and mouse models, highlighting Akkermansia and Prevotellaceae as potential biomarkers. FTY720-Mitoxy therapy beneficially altered gut microbiota in MSA mouse models, supporting cross-species translational research and therapeutic potential.

Increased mucin-degrading Akkermansia is an early gut microbiome marker in iRBD, while the loss of SCFA-producing bacteria is specific to established Parkinson’s disease, suggesting distinct microbial signatures for disease staging and prevention strategies.

This study found distinct gut microbiome signatures in Parkinson’s patients with and without constipation, identifying key microbial genera linked to clinical symptoms, suggesting gut microbiota alterations may contribute to PD pathogenesis and symptom severity.

This cohort study identified a distinct gut microbiome signature in Polish Parkinson’s disease patients, with increased diversity and enrichment of mucin-degrading and pro-inflammatory taxa, notably Akkermansia muciniphila, supporting the potential for microbiome-based biomarkers and interventions in PD.

This study demonstrates significant dysbiosis in the deep nasal sinus microbiota of Parkinson’s disease patients, marked by increased pro-inflammatory pathobionts and loss of beneficial commensals, with specific taxa correlating to symptom severity, suggesting a role for nasal microbiota in PD pathogenesis.

This study used shotgun metagenomics to reveal distinctive taxonomic and functional gut microbiome signatures in central Chinese Parkinson’s disease patients, including increased Bilophila wadsworthia, BCAA transport, and decreased Prevotella, supporting the utility of microbiome-based biomarkers and therapeutic targeting in PD.

This study found that Parkinson’s disease patients have a distinct faecal eukaryotic microbiota, characterized by reduced diversity and a striking increase in Geotrichum candidum, highlighting a potential fungal signature for PD and the need for broader microbiome profiling in neurodegenerative disorders.

Altered Actinobacteria and Firmicutes gut microbiota, and their associated epitopes, are strongly linked to inflammation and metabolic changes in Parkinson’s disease, suggesting novel mechanisms underlying PD pathogenesis and offering potential new biomarkers for diagnosis and intervention.

This study links increased sigmoid mucosal oligomeric α-synuclein and proinflammatory duodenal microbiota with Parkinson’s disease, highlighting the OSyn/αSyn ratio as a potential biomarker and suggesting microbiome signatures for early PD diagnosis and intervention.

Indian PD patients show gut microbiome dysbiosis, notably reduced SCFA producers and increased Clostridia UCG_014. Specific taxa, including Akkermansia and Bacteroides, correlate with constipation. These findings support microbiome-based biomarkers and therapeutic strategies for PD, tailored to Indian populations.